Loftus Peak’s Moderna MRNA Stock Holding History

Loftus Peak’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-255,836	Closed	-$17.9M	–	27
2026 Q2	$17.9M	Buy	+255,836	New	+$13.2M	2.44%	18

Other funds holding MRNA

Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return

Beau Ventures Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return

Lingotto Investment Management London, United Kingdom $5.74B AUM 42.24% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 32.98% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Loftus Peak's MRNA Position: Q3 2026 in Review

Loftus Peak sold out of Moderna (MRNA) in Q3 2026, closing a stake of 255,836 shares — an estimated $17.9M sold.

Loftus Peak first reported a position in MRNA in Q2 2026 and held it in 1 quarter. The position peaked at $17.9M in Q2 2026. 316 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

Loftus Peak reported no remaining Moderna position as of Q3 2026 after selling out during the quarter.
Loftus Peak sold 255,836 Moderna shares in Q3 2026, an estimated $17.9M.
Loftus Peak first reported a position in Moderna in Q2 2026 and held it in 1 quarter.
Loftus Peak's Moderna position peaked at $17.9M in Q2 2026.
316 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Loftus Peak's 13F filing for Q3 2026, filed 15 Oct 2026.